Telix Pharmaceuticals Limited American Depositary Shares (TLX)
Telix Pharmaceuticals Limited American Depositary Shares (TLX) is listed on Nasdaq, where it has traded since November 13, 2024.
- Listed On
- Nasdaq
- Listed Since
- November 13, 2024
- Employees
- 1,184
- Market Cap
- $3.3B
About Telix Pharmaceuticals Limited American Depositary Shares
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 61 institutions reported holding TLX, with 3.0 million shares worth $34.9 million in aggregate. The largest reported holder was FMR, with 561,206 shares worth $6.5 million. Of the 5 largest holders listed below, 1 opened a new position in TLX, 1 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 561,206 | $6M | Reduced 0.63% |
| Lazard Asset Management | 284,207 | $3M | Reduced 1.97% |
| Portland Investment Counsel | 266,200 | $3M | Unchanged |
| Private Advisor Group | 197,250 | $2M | Added 13.09% |
| Marshall Wace | 189,188 | $2M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TLX?
Telix Pharmaceuticals Limited American Depositary Shares (TLX) is listed on Nasdaq, where it has traded since November 13, 2024.
Who are the largest institutional holders of TLX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TLX were FMR, Lazard Asset Management and Portland Investment Counsel.
How many institutions own TLX?
61 institutions reported a position in TLX for the quarter ended June 30, 2026, worth $34.9 million in total.
Did institutions buy or sell TLX last quarter?
Of the 5 largest reported holders, 1 opened a new position in TLX, 1 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TLX.
Every reported institutional holder, plus insider and congressional trades in TLX, on SentiSense.